NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive(R) Demonstrates Expanding EMEA Business at Eurospine 2014 With Surgeon Workshops and Innovative Product Exhibition
Product Demonstrations and Spine Procedure Workshops Highlight Commitment to Serving the Needs of Patients and Surgeons in Europe; Company Also Announces Opening of New European Center of Excellence in Amsterdam

SAN DIEGO, CA -- (Marketwired) -- 10/01/14 -- NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, today announced that the Company will exhibit its innovative portfolio of spinal products at Eurospine 2014, which is being held October 1-3, 2014 in Lyon, France. NuVasive will also provide attending surgeons with workshops addressing the best practices for minimally invasive spine procedures as part of the Company's commitment to serve the needs of patients and surgeons in Europe.

As part of the product exhibition, NuVasive will highlight its industry-leading products and procedures including XLIF®, a minimally invasive surgical (MIS) procedure pioneered by NuVasive that is performed through the side of the body utilizing proprietary neuromonitoring and an integrated portfolio of instruments and specialized implants for treating a range of spinal pathologies. This year, NuVasive is scheduled to participate in the following events at Eurospine 2014:

  • NuVasive Lunch Workshop: NuVasive, along with surgeon proctors Dr. Pedro Berjano, Italy and Prof. Dr. med. Markus Quante, Prof. Dr. med. Markus Quante, Germany will lead a two-hour lunch workshop discussing XLIF for Deformity and Advanced Applications. The workshop will be held from 12:00 to 14:00 UTC on Thursday, October 2 in Saint Clair 2 room.

  • NuVasive Exhibit Stand #B20: The NuVasive exhibit stand will feature a number of innovative minimally disruptive products and procedures, including: XLIF, MAS® PLIF, MAS® TLIF Armada®, Precept®, Cervical Portfolio, Biologics, Bendini® and IOS™.

NuVasive's annual presence at Eurospine is an extension of the Company's continued investment in its strategic expansion throughout the EMEA market. Concurrent with Eurospine 2014, Nuvasive also announced the opening of the Company's European Center of Excellence (COE) in Amsterdam.

The Center will serve as NuVasive's European commercial headquarters and function as the commercial hub for the European executive leadership and departments across marketing, surgeon education, sales, human resources, legal and other support functions. Meanwhile, the International Operations Center in Ireland, which was established in June, will remain the Company's international operational headquarters.

Russell Powers, Executive Vice President of International for NuVasive said, "Region specific events such as Eurospine are essential to our expansion efforts in Europe. The COE, along with the recently opened International Operations Center in Ireland, provide further infrastructure for NuVasive to execute on our market share taking strategy across Western Europe and the entire EMEA region. As the spine market continues to shift toward less invasive solutions, NuVasive is well-positioned, as a leading innovator in minimally invasive spine procedures and other less invasive solutions, to drive surgeon adoption of these solutions across Europe."

Paul Kosters, Senior Vice President of the EMEA branch said, "The opening of the COE is an important milestone for NuVasive and a key inflection point for our Company's strategy to expand in EMEA. In the past year, we have expanded our footprint to include Spain and Poland. Additionally, we continued to build out our world-class leadership team in EMEA with the recent appointment of Phil Bradshaw as Managing Director for the United Kingdom. Phil brings nearly 20 years of experience in the medical device industry, including a decade with DePuy Synthes and most recently with Stryker. Phil's extensive experience in various markets across Europe will be highly complementary as we continue to execute against our market share-taking strategy."

For more information about NuVasive, visit and for more information about Eurospine 2014, visit

About Eurospine:

Eurospine, the Spine Society of Europe, was founded in June 26, 1998, in Innsbruck, Austria. The purpose of Eurospine is to provide a platform in European countries for the exchange of knowledge and ideas in the field of research, prevention, and treatment of spine diseases.

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally-integrated solutions for the spine. The Company is the third largest player in the $8.2 billion global spine market. NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS, platform for lateral spine fusion. MAS was designed to provide safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

NuVasive cautions you that statements included in this press release or during Eurospine 2014 that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, expansion of our network of sales representatives, and the other risks and uncertainties described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Source: NuVasive, Inc.